Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV - Wikidata - awgldk - TriplyDB

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

http://www.wikidata.org/entity/Q26799712

about

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy.Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988-2013.Dolutegravir/rilpivirine for the treatment of HIV-1 infection

P2860

Q36162401-F65DE5EE-2C24-4223-B08D-1F058E791274 Q37375073-83B022CE-667C-4131-91CB-C55DA60DD7DF Q38601891-0D13E39A-C6E7-4143-90D9-F1B0F874DEA6 Q38774333-F829B745-220B-4636-AD3D-280433F79302 Q39004638-B31B9261-A4C2-45E9-AF4C-7682E1905DF8 Q40092935-8CB4D8D5-F785-4853-9297-170FCC918C3A Q40446339-58E618B0-30CC-4CF9-ADF0-B695282622EB Q40517770-09463DFD-4157-489E-88B8-26AFF7B77B8C Q41711863-4D62F2E3-D58A-484A-9EFC-2A807BFBE375 Q47145824-0AC01A82-22E1-4238-A91D-E118516A343C Q47301806-1C8CEFFD-9A5F-42F8-A567-89485714390F Q52571194-FE0BBDD0-94A9-42E8-8BF4-B1AE447A6577 Q55095901-0B34C431-480A-436A-A80A-0C3D74BA11D2 Q59135153-E803633F-914E-44B6-A624-0DFE052502B3

P2860

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

http://www.wikidata.org/entity/Q26799712

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@ast

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@en

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@nl

type

label

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@ast

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@en

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@nl

prefLabel

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@ast

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@en

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@nl

P1433

Q26799712-56073BD1-73D3-4000-BEA4-01CD20A0C0D2

P1476

Q26799712-06D0FBF4-4E84-48B8-9A2F-48FC30DED0F9

P2093

Q26799712-B4DD0959-1EEF-43F3-B154-B2151C0C36C9

P275

Q26799712-52508991-7CB5-4AEF-BB6C-436C712A75A4

P2860

Q26799712-069225A3-E778-4E21-8BEC-73058F195D47

Q26799712-0728F38B-66B5-4448-913F-993C721022DC

Q26799712-083AF2DE-F35B-44D0-8510-12B2081333E1

Q26799712-0AB9240B-4910-4803-B562-184B374B9A6A

Q26799712-0B4052CC-7D3D-492B-A60A-6F525638BAC9

Q26799712-0CDCE698-5DCC-4B1C-9B0B-2258D5658FCA

Q26799712-0FB6CDE4-CFD5-46B2-9B8A-915ADB334469

Q26799712-11DFA24A-A1A5-4582-B1B6-EB1FE544E917

Q26799712-13314B9D-FAA7-41E9-9781-59C55C1125EE

Q26799712-14ACF448-7F9A-4E88-BCEA-52CE1747F3BA

P304

Q26799712-DB57B50C-B50F-4C2B-952F-842250146277

P31

Q26799712-667DF4E5-54C3-4EBF-89DA-A3FC5B173FB5

Q26799712-A8131A24-2429-4F20-87F8-FA21AB5DF233

P3181

Q26799712-F8165B9A-2243-4F7B-849D-F0BE797E821D

P356

Q26799712-5C484328-7870-4916-9F60-1E90CB41DE90

P407

Q26799712-711C9259-417A-40F6-99A3-C5D174896E09

P478

Q26799712-1ACBE6EC-27FE-4FEB-8FB5-1EC3DE260835

P50

Q26799712-F9CC723C-098D-4E28-86CE-257288DAD834

P5008

Q26799712-F9049C00-17C9-4FDC-84F7-723FA7E50FEE

P577

Q26799712-7D532F02-C807-401C-8F0D-10F4C58E4F0F

P698

Q26799712-169C89E0-DF22-4C21-9ED8-26CED44C0746

P921

Q26799712-1238AD89-F2CD-40D6-9173-E2E2248ADCCA

Q26799712-8D246680-C85B-4EE0-BC92-538A84AAC706

Q26799712-99296059-6357-4AE3-93A4-7097C4AF74C9

Q26799712-A6F07888-5AD5-4E37-8EDC-7AC6069F9879

Q26799712-F21355F6-066D-472C-8B07-0996E706DCC1

Q26799712-F5B3C922-B09A-4461-9177-1BD4888808F5

P932

Q26799712-BE68CD75-6DA1-48D1-A520-1F2E3FF9DD1F

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

@en

P2093

Christopher E Kandel

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

P304

3547-3555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1972438

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S84850

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2015-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26185421

http://www.w3.org/2001/XMLSchema#string

P921

human immunodeficiency virus infectious disease

Retroviridae infectious disease

heterocyclic compound

mechanism of action

P932

4500604

http://www.w3.org/2001/XMLSchema#string